

Supplementary Table 1: Sensitivity analysis for vaccine effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections: VERSUS study, Japan, July–September 2021

	Adjusted odds ratio (95% CI)	Vaccine effectiveness (%) (95% CI)
Full vaccination		
Patients aged 16 to 64 years		
BNT162b2 or mRNA-1273		
No vaccination	1.000	
Scenario A	0.116 (0.062 to 0.216)	88.4 (78.4 to 93.8)
Scenario B	0.112 (0.060 to 0.210)	88.8 (79.0 to 94.0)
Scenario C	0.093 (0.046 to 0.187)	90.7 (81.3 to 95.4)
Scenario D	0.114 (0.061 to 0.213)	88.6 (78.7 to 93.9)
BNT162b2		
No vaccination	1.000	
Scenario A	0.134 (0.068 to 0.267)	86.6 (73.3 to 93.2)
Scenario B	0.133 (0.067 to 0.263)	86.7 (73.7 to 93.3)
Scenario C	0.130 (0.064 to 0.264)	87.0 (73.6 to 93.6)
mRNA-1273		
No vaccination	1.000	
Scenario A	0.035 (0.044 to 0.278)	96.5 (72.2 to 99.6)
Scenario B	0.034 (0.004 to 0.269)	96.6 (73.1 to 99.6)
Scenario C	N/A*	N/A*
Patients aged ≥65 years		
BNT162b2 or mRNA-1273		
No vaccination	1.000	
Scenario A	0.098 (0.036 to 0.267)	90.2 (73.3 to 96.4)
Scenario B	0.098 (0.036 to 0.266)	90.2 (73.4 to 96.4)
Scenario C	0.123 (0.045 to 0.333)	87.7 (66.7 to 95.5)
Scenario D	0.113 (0.042 to 0.303)	88.7 (69.7 to 95.8)
BNT162b2		
No vaccination	1.000	
Scenario A	0.142 (0.050 to 0.406)	85.8 (59.4 to 95.0)
Scenario B	0.142 (0.050 to 0.406)	85.8 (59.4 to 95.0)
Scenario C	0.155 (0.054 to 0.442)	84.5 (55.8 to 94.6)

Abbreviations: mRNA, messenger RNA; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VERSUS, Vaccine Effectiveness Real-

time Surveillance for SARS-CoV-2; CI, confidence interval.

Scenario A, for those without precise vaccination dates, we set the most recent possible dates from symptom onset as vaccination dates.

Scenario B, for those without precise vaccination dates, we set the earliest possible dates from symptom onset as vaccination date.

Scenario C, patients with no information of vaccination date were excluded.

Scenario D, multiple imputations were performed for those whose COVID-19 vaccination histories were not documented.

Full vaccination was defined as receiving two doses ≥ 14 days before the symptom onset.

*We could not evaluate the odds ratio because the odds ratio was tiny, almost zero.